2. Apoptosis
  3. TNF Receptor
  4. Certolizumab pegol

Certolizumab pegol  (Synonyms: Certolizumab; CDP870)

Cat. No.: HY-P9953 Purity: 99.30%
SDS COA

Molarity Calculator

Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research.

For research use only. We do not sell to patients.

CAS No. : 428863-50-7

Size Price Stock Quantity
1 mg USD 180 In-stock
5 mg USD 380 In-stock
10 mg USD 600 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Certolizumab pegol Related Antibodies

Top Publications Citing Use of Products

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research[1][2].

In Vitro

Certolizumab pegol (Certolizumab) neutralizes soluble TNFα with an IC90 of 3 ng/mL[2].
Certolizumab pegol (0-100 μg/mL, 1 h) completely inhibits subsequent production of IL-1β in response to LPS in human monocytes[2].
Certolizumab pegol does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC)[2].
Certolizumab pegol does not induce apoptosis of activated human monocytes or peripheral blood lymphocytes (PBLs) or result in degranulation or loss of cell membrane integrity in polymorphonuclear cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Certolizumab pegol Related Antibodies
In Vivo

Certolizumab pegol (Certolizumab) (10 μg; i.p.; single dose) reduces the severity of acute pancreatitis[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Healthy Wistar Albino male rats weighing 180 to 200 g, acute edematous pancreatitis was induced via intraperitoneal injection of 80 μg/kg Cerulein (HY-A0190) (20 μg/kg, 4 times at 1-hour intervals)[3]
Dosage: 10 μg
Administration: Intraperitoneal administration, single dose
Result: Significantly decreased the serum levels of amylase, lipase, and lactate dehydrogenase. Histopathological edema, hemorrhage, parenchymal necrosis, and infiltration scores were also decreased, along with a decrease in malondialdehyde, myeloperoxidase, TNF-α, and caspase-3 activities.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Certolizumab pegol]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Fab'-G1-kappa
Purity & Documentation

Purity: 99.30%

SDS (251 KB)

COA (231 KB)

Inhibitory Antibodies User Guide (602 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Certolizumab pegol Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Certolizumab pegol428863-50-7Certolizumab CDP870CDP870CDP 870CDP-870TNF ReceptorTumor Necrosis Factor ReceptorTNFRrheumatoid arthritisCrohn diseaseIL-1βacute pancreatitisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Certolizumab pegol
Cat. No.:
HY-P9953
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.